Alluvi Labs develops and evaluates premium peptides, supplements, and advanced research compounds for controlled scientific study.
All products are produced exclusively for controlled research and development purposes, guided by science. Not for human or veterinary consumption.
Engineered for research precision. PEPTIDE RESEARCH
Premium research-grade peptides for controlled laboratory study
£40.00
£80.00
£60.00
Part of Alluvi Labs’ ongoing research program into advanced GLP-1 multi-agonist compounds.
Order management, dosing logs, and payment tools in one streamlined research portal.
Track research parameters with clear dashboards and downloadable reports.
Simplified ordering with verified lab credentials and encrypted transactions.
FEATURED RESEARCH
Alluvi pens are pre-filled and ready for evaluation – no reconstitution, no guesswork. Designed for consistent weekly dosing in controlled research protocols.
Self-measured doses with smart tracking for effortless administration – every week, easy to stay consistent.
SUPPLEMENT BOX
Daily gummies for energy, sleep, recovery, and stress – curated for optimal support during your fat-loss journey.
Essential micronutrients and targeted support compounds in convenient daily formats.
Alluvi pens are ready to use – no mixing, no guesswork. Just smart weight loss with self-measured doses and effortless administration – every week, easy to stay consistent.
From weight loss injections to powerful gummies, Alluvi keeps your health goals on track with smart monitoring, nutrition support, and weekly weight-loss insights – all in one seamless system.
The following data is drawn from published peer-reviewed clinical research. Alluvi supplies Retatrutide pens exclusively for laboratory research and development purposes.
Alluvi does not promote or imply medical or human use of its products. Data shown reflects published clinical trial outcomes and is provided for research reference only.
24.2%
Mean weight reduction at 48 weeks (12 mg dose). Source: Jastreboff et al., NEJM 2023.
17.5%
Comparative weight loss under dietary restriction. Source: Published trial data.
89%
Patient-reported outcomes from clinical survey data.
30.8 lbs
Equivalent to ~14 kg at 48 weeks. Source: Jastreboff et al., NEJM 2023.
References: Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity ? A Phase 2 Trial." N Engl J Med. 2023;389:514-526. PubMed
From research-grade compounds to structured data collection and nutritional analysis – Alluvi provides an integrated system designed for serious research.
Stay on track with monthly research supply boxes.
Pre-filled Retatrutide systems – sleek, pre-measured, and designed for evaluation in controlled research protocols.
Integrated dashboards for research data logging and progress visualization.
Daily gummies for energy, sleep, recovery, and stress – curated for optimal support during your fat-loss journey.
Our compounds and supplements are supplied for R&D purposes only, with a foundation in published scientific literature.